Pyxis Oncology Draws Buy at Stifel on Lead Asset
Pyxis Oncology Price Target Announced at $10.00/Share by Stifel
Pyxis Oncology Initiated at Buy by Stifel
RBC Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7
Analysts Have Conflicting Sentiments on These Healthcare Companies: Morphic Holding (MORF), Pyxis Oncology (PYXS) and Zynex (ZYXI)
Institutional Owners May Ignore Pyxis Oncology, Inc.'s (NASDAQ:PYXS) Recent US$25m Market Cap Decline as Longer-term Profits Stay in the Green
Express News | Pyxis Oncology Expands Board of Directors With Appointment of Michael a. Metzger
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Hims & Hers Health (HIMS) and Cytokinetics (CYTK)
Pyxis Oncology | 10-Q: Q1 2024 Earnings Report
Pyxis Oncology 1Q Research and Development Expenses $13.0M >PYXS
Pyxis Oncology 1Q Loss/Shr 6c >PYXS
Earnings Flash (PYXS) PYXIS ONCOLOGY Posts Q1 Revenue $16.1M
Express News | Pyxis Oncology Inc - Expected Cash Runway Into 2H 2026
Express News | Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
Express News | Pyxis Oncology Q1 Basic EPS USD -0.06
Express News | Pyxis Oncology Q1 Income From Operations USD -5.605 Million Vs. Ibes Estimate USD -14.4 Million
Express News | Pyxis Oncology Q1 Net Income USD -3.256 Million Vs. Ibes Estimate USD -13 Million
Pyxis Oncology Coverage Assumed by Jefferies at Buy
Express News | Pyxis Oncology Inc : Jefferies Assumes Coverage With Buy Rating; Price Target $10
HROW, HCAT and EGRX Are Among After Hour Movers
No Data